Osteopontin as a biomarker for osteosarcoma therapy and prognosis (Review)
- Authors:
- Xingwen Han
- Wenji Wang
- Jingjing He
- Lei Jiang
- Xun Li
-
Affiliations: Department of Orthopedics, First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Department of Liver Diseases, Second Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Department of Oncology Surgery, First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Department of General Surgery, First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China - Published online on: January 8, 2019 https://doi.org/10.3892/ol.2019.9905
- Pages: 2592-2598
-
Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Singh K, Mukherjee AB, De Vouge MW and Mukherjee BB: Differential processing of osteopontin transcripts in rat kidney- and osteoblast-derived cell lines. J Biol Chem. 267:23847–23851. 1992.PubMed/NCBI | |
|
Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Simpson S, Dunning MD, de Brot S, Grau-Roma L, Mongan NP and Rutland CS: Comparative review of human and canine osteosarcoma: Morphology, epidemiology, prognosis, treatment and genetics. Acta Vet Scand. 59:712017. View Article : Google Scholar : PubMed/NCBI | |
|
Longhi A, Errani C, De Paolis M, Mercuri M and Bacci G: Primary bone osteosarcoma in the pediatric age: State of the art. Cancer Treat Rev. 32:423–436. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Selmic LE, Burton JH, Thamm DH, Withrow SJ and Lana SE: Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma. J Veterin Internal Med. 28:554–563. 2014. View Article : Google Scholar | |
|
Reddy KI, Wafa H, Gaston CL, Grimer RJ, Abudu AT, Jeys LM, Carter SR and Tillman RM: Does amputation offer any survival benefit over limb salvage in osteosarcoma patients with poor chemonecrosis and close margins? Bone Joint J. 97-B:115–120. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrari S and Serra M: An update on chemotherapy for osteosarcoma. Exp Opin Pharmacother. 16:2727–2736. 2015. View Article : Google Scholar | |
|
Wang WG, Wan C and Liao GJ: The efficacy of high-dose versus moderate-dose chemotherapy in treating osteosarcoma: A systematic review and meta-analysis. In J Clin Exp Med. 8:15967–15974. 2015. | |
|
Zhang FY, Tang W, Zhang ZZ, Huang JC, Zhang SX and Zhao XC: Systematic review of high-dose and standard-dose chemotherapies in the treatment of primary well-differentiated osteosarcoma. Tum Biol. 35:10419–10427. 2014. View Article : Google Scholar | |
|
Ta HT, Dass CR, Choong PF and Dunstan DE: Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Tang N, Song WX, Luo J, Haydon RC and He TC: Osteosarcoma development and stem cell differentiation. Clin Orthop Rel Res. 466:2114–2130. 2008. View Article : Google Scholar | |
|
Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Allen JI and Moore MN: Environmental prognostics: Is the current use of biomarkers appropriate for environmental risk evaluation? Mar Environ Res. 58:227–232. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Chaturvedi S and McCrae KR: Clinical risk assessment in the antiphospholipid syndrome: Current landscape and emerging biomarkers. Curr Rheumatol Rep. 19:432017. View Article : Google Scholar : PubMed/NCBI | |
|
Moutzouri E, Tsimihodimos V and Tselepis AD: Inflammatory biomarkers and cardiovascular risk assessment. Current knowledge and future perspectives. Curr Pharm Design. 19:3827–3840. 2013. View Article : Google Scholar | |
|
Dijkstra S, Mulders PF and Schalken JA: Clinical use of novel urine and blood based prostate cancer biomarkers: A review. Clin Biochem. 47:889–896. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kai K, Dittmar RL and Sen S: Secretory microRNAs as biomarkers of cancer. Semin Cell Develop Biol. 2017. | |
|
Li S, Liu X, Liu T, Meng X, Yin X, Fang C, Huang D, Cao Y, Weng H, Zeng X and Wang X: Identification of Biomarkers Correlated with the TNM Staging and Overall Survival of Patients with Bladder Cancer. Front Physiol. 8:9472017. View Article : Google Scholar : PubMed/NCBI | |
|
Van Loon K and Venook AP: Biomarkers in colon cancer: The chasm between expectations and reality. Oncology (Williston Park). 27:758–763. 2013.PubMed/NCBI | |
|
Senger DR, Wirth DF and Hynes RO: Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 16:885–893. 1979. View Article : Google Scholar : PubMed/NCBI | |
|
Franzen A and Heinegard D: Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J. 232:715–724. 1985. View Article : Google Scholar : PubMed/NCBI | |
|
Rangaswami H, Bulbule A and Kundu GC: Osteopontin: Role in cell signaling and cancer progression. Trends Cell Biol. 16:79–87. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kazanecki CC, Uzwiak DJ and Denhardt DT: Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem. 102:912–924. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Tuck AB, Chambers AF and Allan AL: Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management. J Cell Biochem. 102:859–868. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Cao DX, Li ZJ, Jiang XO, Lum YL, Khin E, Lee NP, Wu GH and Luk JM: Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol. 18:3923–3930. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Denhardt DT and Guo X: Osteopontin: A protein with diverse functions. FASEB J. 7:1475–1482. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
El-Tanani MK: Role of osteopontin in cellular signaling and metastatic phenotype. Front Biosci. 13:4276–4284. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Boldrini L, Donati V, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F and Fontanini G: Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Brit J Cancer. 93:453–457. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF and Casson AG: Osteopontin expression in lung cancer. Lung Cancer. 15:311–323. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han N, Ma Y, Di X, Gao M, et al: Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res. 11:4646–4652. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ and Gandara DR: SWOG Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 26:4771–4776. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ostheimer C, Bache M, Guttler A, Reese T and Vordermark D: Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer. BMC Cancer. 14:8582014. View Article : Google Scholar : PubMed/NCBI | |
|
Ostheimer C, Gunther S, Bache M, Vordermark D and Multhoff G: Dynamics of heat shock protein 70 serum levels as a predictor of clinical response in non-small-cell lung cancer and correlation with the hypoxia-related marker osteopontin. Front Immunol. 8:13052017. View Article : Google Scholar : PubMed/NCBI | |
|
Ostheimer C, Schweyer F, Reese T, Bache M and Vordermark D: The relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small-cell lung cancer. Oncology Lett. 12:3449–3456. 2016. View Article : Google Scholar | |
|
Schneider S, Yochim J, Brabender J, Uchida K, Danenberg KD, Metzger R, Schneider PM, Salonga D, Hölscher AH and Danenberg PV: Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res. 10:1588–1596. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Shi L and Wang X: Role of osteopontin in lung cancer evolution and heterogeneity. Sem Cell Develop Biol. 64:40–47. 2017. View Article : Google Scholar | |
|
Wang M, Han J, Marcar L, Black J, Liu Q, Li X, Nagulapalli K, Sequist LV, Mak RH, Benes CH, et al: Radiation Resistance in kras-mutated lung cancer is enabled by stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res. 77:2018–2028. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Anborgh PH, Caria LB, Chambers AF, Tuck AB, Stitt LW and Brackstone M: Role of plasma osteopontin as a biomarker in locally advanced breast cancer. Am J Transl Res. 7:723–732. 2015.PubMed/NCBI | |
|
Das R, Mahabeleshwar GH and Kundu GC: Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem. 278:28593–28606. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Gu M and Zheng X: Osteopontin and vasculogenic mimicry formation are associated with response to neoadjuvant chemotherapy in advanced breast cancer. OncoTargets Ther. 10:4121–4127. 2017. View Article : Google Scholar | |
|
Psyrri A, Kalogeras KT, Wirtz RM, Kouvatseas G, Karayannopoulou G, Goussia A, Zagouri F, Veltrup E, Timotheadou E, Gogas H, et al: Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the hellenic cooperative oncology group. J Transl Med. 15:302017. View Article : Google Scholar : PubMed/NCBI | |
|
Tuck AB and Chambers AF: The role of osteopontin in breast cancer: Clinical and experimental studies. J Mamm Gland Biolo Neopl. 6:419–429. 2001. View Article : Google Scholar | |
|
Zduniak K, Agrawal A, Agrawal S, Hossain MM, Ziolkowski P and Weber GF: Osteopontin splice variants are differential predictors of breast cancer treatment responses. BMC Cancer. 16:4412016. View Article : Google Scholar : PubMed/NCBI | |
|
Ding L and Zheng S: Expression and clinical significance of osteopontin in colorectal cancer and liver metastatic tissues. Zhonghua wai ke za zhi. 40:773–775. 2002.(In Chinese). PubMed/NCBI | |
|
Ding L, Zheng S and Cao J: Expression of osteopontin mRNA and its protein in colorectal cancer and liver metastatic tissues. Zhonghua yi xue za zhi. 82:970–973. 2002.(In Chinese). PubMed/NCBI | |
|
Gu X, Gao XS, Ma M, Qin S, Qi X, Li X, Sun S, Yu H, Wang W and Zhou D: Prognostic significance of osteopontin expression in gastric cancer: A meta-analysis. Oncotarget. 7:69666–69673. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Imano M, Okuno K, Itoh T, Satou T, Ishimaru E, Yasuda T, Hida J, Imamoto H, Takeyama Y and Shiozaki H: Osteopontin induced by macrophages contribute to metachronous liver metastases in colorectal cancer. Am Surg. 77:1515–1520. 2011.PubMed/NCBI | |
|
Ito T, Hashimoto Y, Tanaka E, Kan T, Tsunoda S, Sato F, Higashiyama M, Okumura T and Shimada Y: An inducible short-hairpin RNA vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo. Clin Cancer Res. 12:1308–1316. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kolb A, Kleeff J, Guweidhi A, Esposito I, Giese NA, Adwan H, Giese T, Büchler MW, Berger MR and Friess H: Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Canc Biol Ther. 4:740–746. 2005. View Article : Google Scholar | |
|
Lazar M, Sullivan J, Chipitsyna G, Gong Q, Ng CY, Salem AF, Aziz T, Witkiewicz A, Denhardt DT, Yeo CJ and Arafat HA: Involvement of osteopontin in the matrix-degrading and proangiogenic changes mediated by nicotine in pancreatic cancer cells. J Gastroint Surgery. 14:1566–1577. 2010. View Article : Google Scholar | |
|
Li JJ, Li HY and Gu F: Diagnostic significance of serum osteopontin level for pancreatic cancer: a meta-analysis. Gen Test Mol Biomarkers. 18:580–586. 2014. View Article : Google Scholar | |
|
Lin J, Myers AL, Wang Z, Nancarrow DJ, Ferrer-Torres D, Handlogten A, Leverenz K, Bao J, Thomas DG, Wang TD, et al: Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma. Oncotarget. 6:22239–22257. 2015.PubMed/NCBI | |
|
Liu G, Fan X, Tang M, Chen R, Wang H, Jia R, Zhou X, Jing W, Wang H, Yang Y, et al: Osteopontin induces autophagy to promote chemo-resistance in human hepatocellular carcinoma cells. Cancer Lett. 383:171–182. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Loosen SH, Roderburg C, Kauertz KL, Pombeiro I, Leyh C, Benz F, Vucur M, Longerich T, Koch A, Braunschweig T, et al: Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma. J Hepatology. 67:749–757. 2017. View Article : Google Scholar | |
|
Ng L, Wan T, Chow A, Iyer D, Man J, Chen G, Yau TC, Lo O, Foo CC, Poon JT, et al: Osteopontin overexpression induced tumor progression and chemoresistance to oxaliplatin through induction of stem-like properties in human colorectal cancer. Stem Cells Int. 2015:2478922015. View Article : Google Scholar : PubMed/NCBI | |
|
Sulpice L, Rayar M, Desille M, Turlin B, Fautrel A, Boucher E, Llamas-Gutierrez F, Meunier B, Boudjema K, Clément B and Coulouarn C: Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology. 58:1992–2000. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Terashi T, Aishima S, Taguchi K, Asayama Y, Sugimachi K, Matsuura S, Shimada M, Maehara S, Maehara Y and Tsuneyoshi M: Decreased expression of osteopontin is related to tumor aggressiveness and clinical outcome of intrahepatic cholangiocarcinoma. Liver Int. 24:38–45. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T and Tahara E: Co-expression of osteopontin and CD44v9 in gastric cancer. Inte J Cancer. 79:127–132. 1998. View Article : Google Scholar | |
|
Weber CE, Erşahin ÇH, Kuo PC and Mi Z: Pancreatic Cancer and Osteopontin: The Relationship Remains Unclear. Pancreas. 45:e35–e36. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wu H, Zhang H, Hu LY, Zhang TY, Zheng YJ, Shen F and Yang T: Is osteopontin a promising prognostic biomarker for cholangiocarcinoma? J Hepatol. Sep 20–2017.(Epub ahead of print). | |
|
Wu IC, Wu MT, Chou SH, Yang SF, Goan YG, Lee JM, Chou YP, Bair MJ, Wang TE, Chen A, et al: Osteopontin expression in squamous cell cancer of the esophagus. World J Surg. 32:1989–1995. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang HZ, Liu JG, Wei YP, Wu C, Cao YK and Wang M: Expressions of RhoC and osteopontin in esophageal squamous carcinoma and association with the patients' prognosis. Nan Fang Yi Ke Da Xue Xue Bao. 26:1612–1615. 2006.(in Chinese). PubMed/NCBI | |
|
Forootan SS, Foster CS, Aachi VR, Adamson J, Smith PH, Lin K and Ke Y: Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer. 118:2255–2261. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hsieh IS, Huang WH, Liou HC, Chuang WJ, Yang RS and Fu WM: Upregulation of drug transporter expression by osteopontin in prostate cancer cells. Mol Pharmacol. 83:968–977. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Puzone R, Paleari L, Montefiore F, Ruggiero L, Puntoni M, Maffezzini M, Bobbio B, Marroni P, Libener R and Betta PG: Osteopontin plasma level does not detect prostate cancer in patients referred for diagnostic prostate biopsy. Int J Biol Markers. 25:200–206. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tilli TM, Bellahcène A, Castronovo V and Gimba ER: Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines. BMC Cancer. 14:4332014. View Article : Google Scholar : PubMed/NCBI | |
|
Tilli TM, Silva EA, Matos LC, Faget DV, Dias BF, Vasconcelos JS, Yokosaki Y and Gimba ER: Osteopontin is a tumor autoantigen in prostate cancer patients. Oncol Lett. 2:109–114. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Tozawa K, Yamada Y, Kawai N, Okamura T, Ueda K and Kohri K: Osteopontin expression in prostate cancer and benign prostatic hyperplasia. Urol Int. 62:155–158. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Hu ZD, Wei TT, Yang M, Ma N, Tang QQ, Qin BD, Fu HT and Zhong RQ: Diagnostic value of osteopontin in ovarian cancer: a meta-analysis and systematic review. PLoS One. 10:e01264442015. View Article : Google Scholar : PubMed/NCBI | |
|
Leung DT, Lim PL, Cheung TH, Wong RR, Yim SF, Ng MH, Tam FC, Chung TK and Wong YF: Osteopontin fragments with intact thrombin-sensitive site circulate in cervical cancer patients. PLoS One. 11:e01604122016. View Article : Google Scholar : PubMed/NCBI | |
|
Song JY, Lee JK, Lee NW, Yeom BW, Kim SH and Lee KW: Osteopontin expression correlates with invasiveness in cervical cancer. Aust N Z J Obstet Gynaecol. 49:434–438. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wong JPC, Wei R, Lyu P, Tong OLH, Zhang SD, Wen Q, Yuen HF, El-Tanani M and Kwok HF: Clinical and in vitro analysis of Osteopontin as a prognostic indicator and unveil its potential downstream targets in bladder cancer. Int J Biol Sci. 13:1373–1386. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xu C, Li H, Yin M, Yang T, An L and Yang G: Osteopontin is involved in TLR4 pathway contributing to ovarian cancer cell proliferation and metastasis. Oncotarget. 8:98394–98404. 2017.PubMed/NCBI | |
|
Xu ST, Guo C, Ding X, Fan WJ, Zhang FH, Xu WL and Ma YC: Role of osteopontin in the regulation of human bladder cancer proliferation and migration in T24 cells. Mol Med Rep. 11:3701–3707. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zivny JH, Leahomschi S, Klener P Jr..Zivny J, Haluzik M and Cibula D: Comparison of Plasma Osteopontin Levels between patients with borderline ovarian tumours and serous ovarian carcinoma. Folia Biol (Praha). 62:258–262. 2016.PubMed/NCBI | |
|
Jia R, Liang Y, Chen R, Liu G, Wang H, Tang M, Zhou X, Wang H, Yang Y, Wei H, et al: Osteopontin facilitates tumor metastasis by regulating epithelial-mesenchymal plasticity. Cell Death Dis. 7:e25642016. View Article : Google Scholar : PubMed/NCBI | |
|
Bandopadhyay M, Bulbule A, Butti R, Chakraborty G, Ghorpade P, Ghosh P, Gorain M, Kale S, Kumar D, Kumar S, et al: Osteopontin as a therapeutic target for cancer. Exp Opin Therap Targ. 18:883–895. 2014. View Article : Google Scholar | |
|
Raja R, Kale S, Thorat D, Soundararajan G, Lohite K, Mane A, Karnik S and Kundu GC: Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis. Oncogene. 33:2053–2064. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wei R, Wong JPC and Kwok HF: Osteopontin-a promising biomarker for cancer therapy. J Cancer. 8:2173–2183. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S, Cocorullo G, et al: CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 14:342–356. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang N, Ying MD, Wu YP, Zhou ZH, Ye ZM, Li H and Lin DS: Hyperoside, a flavonoid compound, inhibits proliferation and stimulates osteogenic differentiation of human osteosarcoma cells. PLoS One. 9:e989732014. View Article : Google Scholar : PubMed/NCBI | |
|
Mortus JR, Zhang Y and Hughes DP: Developmental pathways hijacked by osteosarcoma. Ad Exp Med Biol. 804:93–118. 2014. View Article : Google Scholar | |
|
Luo X, Chen J, Song WX, Tang N, Luo J, Deng ZL, Sharff KA, He G, Bi Y, He BC, et al: Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest. 88:1264–1277. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Velupillai P, Sung CK, Tian Y, Dahl J, Carroll J, Bronson R and Benjamin T: Polyoma virus-induced osteosarcomas in inbred strains of mice: host determinants of metastasis. PLoS Path. 6:e10007332010. View Article : Google Scholar | |
|
Liu SJ, Hu GF, Liu YJ, Liu SG, Gao H, Zhang CS, Wei YY, Xue Y and Lao WD: Effect of human osteopontin on proliferation, transmigration and expression of MMP-2 and MMP-9 in osteosarcoma cells. Chin Med J. 117:235–240. 2004.PubMed/NCBI | |
|
Liu SJ, Zhang DQ, Sui XM, Zhang L, Cai ZW, Sun LQ, Liu YJ, Xue Y and Hu GF: The inhibition of in vivo tumorigenesis of osteosarcoma (OS)-732 cells by antisense human osteopontin RNA. Cell Mol Biol Lett. 13:11–19. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Berge G, Pettersen S, Grotterød I, Bettum IJ, Boye K and GM Ml: Osteopontin-an important downstream effector of S100A4-mediated invasion and metastasis. Int J Cancer. 129:780–790. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Rankin EB and Giaccia AJ: The role of hypoxia-inducible factors in tumorigenesis. Cell Death Different. 15:678–685. 2008. View Article : Google Scholar | |
|
Macheda ML, Rogers S and Best JD: Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Phy. 202:654–662. 2005. View Article : Google Scholar | |
|
Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hsieh IS, Yang RS and Fu WM: Osteopontin upregulates the expression of glucose transporters in osteosarcoma cells. PLoS One. 9:e1095502014. View Article : Google Scholar : PubMed/NCBI | |
|
Song K, Liu N, Yang Y and Qiu X: Regulation of osteosarcoma cell invasion through osteopontin modification by miR-4262. Tum Biol. 37:6493–6499. 2016. View Article : Google Scholar | |
|
Noda M, Yoon K, Prince CW, Butler WT and Rodan GA: Transcriptional regulation of osteopontin production in rat osteosarcoma cells by type beta transforming growth factor. J Biol Chem. 263:13916–13921. 1988.PubMed/NCBI | |
|
Wong IH, Chan AT and Johnson PJ: Quantitative analysis of circulating tumor cells in peripheral blood of osteosarcoma patients using osteoblast-specific messenger RNA markers: A pilot study. Clin Cancer Res. 6:2183–2188. 2000.PubMed/NCBI | |
|
Sulzbacher I, Birner P, Trieb K, Lang S and Chott A: Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virch Arch. 441:345–349. 2002. View Article : Google Scholar |
